Loading news...
Investors seeking protection from geopolitical volatility and stubborn inflation in 2026 may find opportunity in short-term bonds, where active management has historically delivered returns 25% higher than passive strategies, according to Vontobel Asset Management. Research going back to the 1990s shows investors in short-term, high-quality corporate bonds typically earn total returns of 1.
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) announced today that it will present a range of next‑generation automated workflow innovations at the SLAS2026 International Conference & Exhibition, taking place February 7–11 in Boston, Massachusetts. Agilent will demonstrate how its expanding automation ecosystem—integrating advanced imaging, software, robotics, and AI‑powered optimization—supports laboratories in accelerating discovery with confidence, efficiency,.
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) will release financial results for the first quarter of fiscal year 2026 after the stock market closes on Wednesday, Feb. 25. The company will host a conference call to discuss the results at 1:30 p.m. PST the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's Investor Relations website. A recording of the call also will be available on the website for 90 days. Abo.
Bank of New York Mellon Corp cut its holdings in shares of Agilent Technologies, Inc. (NYSE: A) by 3.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,012,132 shares of the medical research company's stock after selling 75,746 shares
Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Agilent Technologies (A). But which of these two companies is the best option for those looking for undervalued stocks?
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent S540MD Slide Scanner System, a whole slide imaging (WSI) digital scanner, available for sale in key European markets. The launch reflects Agilent's continued investment in digital pathology, expanding its portfolio to meet the growing demand for high-throughput solutions in clinical laboratories. Pathology laboratories worldwide are under increasing pressure to improve diagnostic.
Sequoia Financial Advisors LLC boosted its stake in shares of Agilent Technologies, Inc. (NYSE: A) by 10.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,568 shares of the medical research company's stock after purchasing an additional
SNDL (NASDAQ: SNDL - Get Free Report) and Agilent Technologies (NYSE: A - Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership. Analyst Recommendations This is a breakdown of recent ratings
Agilent Technologies, Inc. (A) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Miracle Mile Advisors LLC cut its stake in shares of Agilent Technologies, Inc. (NYSE: A) by 53.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,257 shares of the medical research company's stock after selling 4,925 shares during the quarter. Miracle
Boston Trust Walden Corp lowered its position in shares of Agilent Technologies, Inc. (NYSE: A) by 17.5% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 229,761 shares of the medical research company's stock after selling 48,731 shares during the period. Boston
Agilent Technologies, Inc. (NYSE: A - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the sixteen analysts that are covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has given a strong buy recommendation to
Agilent (A) reported earnings 30 days ago. What's next for the stock?
Bloomberg's 2026 Dividend Focus list highlights 14 ‘safer' stocks with free cash flow yields exceeding dividend yields, signaling potential buy opportunities. Top projected net gainers for 2026 include Marvell Technology (MRVL), Nike (NKE), and PT Telekom Indonesia (TLK), with analyst-estimated gains up to 37.98%. Four ‘IDEAL' stocks—Aviva, Sodexo, Danske Bank, and Western Midstream—offer dividends from $1,000 invested greater than their share price, meeting the dogcatcher ‘watch to buy' threshold.
Osaic Holdings Inc. grew its holdings in Agilent Technologies, Inc. (NYSE: A) by 35.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 68,053 shares of the medical research company's stock after purchasing an additional 17,817 shares during the period. Osaic Holdings Inc.'s
Corient Private Wealth LLC trimmed its stake in shares of Agilent Technologies, Inc. (NYSE: A) by 3.3% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 185,108 shares of the medical research company's stock after selling 6,313 shares
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell and CFO Adam Elinoff will present at the 44th Annual J.P. Morgan Healthcare Conference at 9 to 9:40 a.m. PST on Tuesday, Jan. 13, 2026. A live audio webcast and replay of the presentation will be available through Agilent's Investor Relations website. About Agilent Technologies Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technolog.
Balyasny Asset Management L.P. decreased its position in Agilent Technologies, Inc. (NYSE: A) by 11.8% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,295,310 shares of the medical research company's stock after selling 173,468 shares during the
Frontier Capital Management Co. LLC cut its position in Agilent Technologies, Inc. (NYSE: A) by 22.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 204,142 shares of the medical research company's stock after selling 58,730 shares during
Pre-Market Stock Futures: The futures are trading flat on Tuesday after we opened the week on the downside, with all major indices finishing the day lower. With the Federal Reserve meeting this week, investors are playing a wait-and-see game before bidding stocks higher to ensure there will indeed be a 25-basis-point cut. Wall Street will... Here Are Tuesday's Top Wall Street Analyst Research Calls: Agilent, Alibaba, Delta Air Lines, Intel, JD.com, Micron Technology, Reddit and More.